Engineering for Life

Trending News

Omni Active Health likely to Invest 150 cr through Strategic Acquisitions

 November 12, 2017, Sunday 

Omni Active Health is planning to invest 150 cr in over 3-4 years. Omni Active Health Technologies, a leading nutraceutical company is looking at strategic acquisitions in domestic and foreign markets.

Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor

  NOV 10, 2017,Friday

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY)  

First disclosure of anti-tumor activity from the bladder and cervical cancer cohorts showed objective response rates of 32% and 14%, respectively, and was 46% and 25% in patients who express PD-L1 ≥1%   Increased proliferating cytotoxic T cell count and decreased kynurenine production were also observed, providing evidence of immunomodulation within the tumor   Safety profile is consistent with that previously reported for the BMS-986205 plus Opdivo combination.


Paris, France - October 12, 2017  

Expansion at Val de Reuil reinforces the company’s position as a global leader in seasonal flu vaccines  

Pneumonia vaccine saves 500,000 lives in world's poorest countries

Geneva, 12 November 2017  

(Ref :GAVI)

Over 109 million children in the developing world have now received pneumococcal conjugate vaccine (PCV) 

What's Happening Today

USFDA issues warning to Lupin

Drug firm Lupin gets warning letter from the US health regulator, Food and Drug Administration (FDA), for its manufacturing facilities in Goa and Pithampur, Indore.

Torrent Pharma to acquire Unichem's India

Ahmedabad-based Torrent group is likely to acquire Unichem Laboratories Ltd in India and Nepal worth Rs.3600 Crore

Roche's Alecensa gets lung cancer treatment approval

Roche's Alecensa is now approved to treat newly diagnosed patients with ALK- positive disease

Exemplary Innovations


Sign up to hear from our team.


Major UK investment to boost influenza vaccine production, jobs and exports

Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults

Merck Receives FDA Approval of PREVYMIS™ (letermovir)


AstraZeneca shares scientific updates


Sanofi, Principia agree to develop multiple sclerosis drug candidate